Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

Inclusion Criteria: For the VCA portion of the study: * Patients referred due to one or more of these conditions: (1) severe facial deformity comprising more than 25% of the facial area and/or one or more of the central facial units (i.e. lip(s), nose, eye(s)), (2) single or bilateral upper limb(s) amputation, where at least one of the limbs was amputated at the level of the wrist or more proximal, up to the functional shoulder joint, and (3) severe abdominal wall defect comprising more than 50% of the functional abdominal wall. * Injuries must have taken place no more than 15 years and no less than 6 months prior to presentation for consideration. * All other conventional reconstruction approaches will have been either exhausted, or ruled out due to poor prognosis of outcomes. * Patients will need to possess strong motivation and a willingness to commit to post-transplant rehabilitation. * Normal renal and hepatic function within acceptable medical parameters For the recombinant IL-2 phase of the study: * At least 3 months have elapsed since the VCA transplant operation * At least 4 weeks on stable immune suppression and steriods (\<5 mg QD). * No addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range for that drug. * Medical evaluations, clinical and laboratory assessments must deem that participants have adequate organ function. * The effects …